SIZE XSSIZE SMSIZE MDSIZE LG

2019 BCOP Annual Conference On-Demand

Please Note: This product is no longer available for purchase. 

Were you unable to attend the HOPA Annual Conference?
Did you miss the opportunity to purchase the HOPA Virtual Conference?
Do you still need BCOP credits?
HOPA has the answer for you!

Advanced level oncology pharmacists seeking quality educational opportunities to meet their Board Certified Oncology Pharmacy (BCOP) recertification requirements will find the 2019 BCOP Annual Conference sessions a great option. Participants can earn up to 8 credit hours toward BCOP and/or Accreditation Council for Pharmacy credit.

Originally presented at the HOPA Annual Conference, the following session recordings are available:

BC1 – Updates in the Management of Prostate Cancer

BC2 – Survivorship in Young Adults and Adolescents: Current and Future Challenges

BC3 – Maintenance Therapy After Hematopoietic Cell Transplantation in AML: The Old, the New, and the Future

BC4 – Current Strategies in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

BC5 – Advances in Breast Cancer: Are We Moving the Needle to Better Survival?

BC6 – Leukemia Is Coming: The Battle of Targeted Therapies in Acute Myeloid Leukemia

BC7 – Updates in the Management of Colorectal Cancer

Each session will involve a recording of the speaker presenting their topic, a pre-test and post-test
Credit Designation

Accreditation Statement:

 logo acpeThe Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. BCOP test must be completed by April 1, 2022.

education speaker bpslogo The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved. Test must be completed by September 30, 2019.

Activity type: Application.

Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.

Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.


Sessions

BC1 - Updates in the Management of Prostate Cancer  

Description: Over the past year, several advances in screening recommendations and treatment of prostate cancer have occurred. This session will provide an update to guideline recommendations for prostate cancer screening, highlighting important differences. Data on the two new available therapies for the treatment of nonmetastatic castration-resistant prostate cancer will be shared as well as guidance that can be used to select the most appropriate treatment for metastatic hormone-sensitive prostate cancer. The session will close with a discussion of genomics in prostate cancer, including what the common mutations are, when to test for mutations, and how to treat if mutations are present.

Learning Objectives

  • Distinguish differences in national guidelines for prostate cancer screening
  • Interpret evidence behind treatment options for non-metastatic castrate-resistant prostate cancer
  • Formulate a first-line treatment recommendation on a patient with metastatic hormone-sensitive prostate cancer
  • Analyze the most appropriate therapy based on tumor or gene mutation results for a patient with metastatic prostate cancer

Speaker: Lisa Holle, PharmD BCOP FHOPA

 Lisa Holle

Dr. Holle completed her Bachelor of Science in Pharmacy and post-baccalaureate Doctor of Pharmacy from the University of Wisconsin–Madison. She completed a specialized oncology residency at UT M.D. Anderson Cancer Center, and is a board-certified oncology pharmacist. Dr. Holle has worked as an oncology pharmacist for over 20 years in a variety of settings including private hospitals, academic medical centers, and medical communications. Currently, Dr. Holle is an Associate Clinical Professor at the UConn School of Pharmacy and Associate Professor at the UConn School of Medicine. Her practice site is at the UConn Health Carole and Ray Neag Comprehensive Cancer Center, where she works in a team-based ambulatory care clinic.

 

Dr. Holle is a Past President of HOPA (Hematology/Oncology Pharmacy Association) and current Treasurer of the International Society of Oncology Pharmacy Practitioners. She is also an active member in many other professional oncology and pharmacy organizations. Dr. Holle’s clinical research program focuses on medical marijuana, numeracy and patient decision-making, oncology quality improvement initiatives, and oral anticancer therapy management. She has authored numerous articles and chapters on oncology and teaching-related topics.

Target Audience
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number UAN 0465-0000-19-032-H04-P.

 

BC2: Survivorship in Young Adults and Adolescents: Current and Future Challenges

Description: This session will focus on how the treatment of cancer may affect the long-term health of patients from adolescents through the elderly. The presenters will review strategies for reducing the impact of late and specific effects of treatment on these patients. Topics will include fertility preservation, strategies to manage hormone-related symptoms, and opportunities to reduce long-term morbidity related to chemotherapy. This session is directed toward those who care for adolescent, young adult, and adult patients and to providers who have an active role in the care of long-term survivors.

Learning Objectives

  • Illustrate how treatment of cancer in adolescent and young adults (AYA) impacts the risk of long-term morbidity in survivors
  • Show opportunities for pharmacists to reduce the incidence of long-term morbidity in AYA receiving chemotherapy
  • Apply treatment strategies to hormone-related symptoms in cancer survivors
  • Choose methods of fertility preservation in young adults/adults with cancer

Speakers: Joseph Sciasci, PharmD BCOP BCPS
Mary Mably, RPh BCOP

 joseph sciasci

Joseph Sciasci is a clinical pharmacy specialist in pediatric oncology and blood/marrow transplantation at The Children's Hospital of Philadelphia. His focus in his current position is on the care of pediatric patients with cancer and those receiving cellular and immunotherapy.

Mary Mably

Mary Mably is Pharmacy Manager, Inpatient Services and the PGY2 Oncology Pharmacy Program Director at UW Health, where she has worked since 2008.  She received her BS in Pharmacy from St. Louis College of Pharmacy in 1983 and has been Board Certified in Oncology Pharmacy since 2002. She serves on 2 NCCN panels, is the co-chairperson of the Vizient Pharmacy Cancer Care Committee, and is an active member of HOPA and ASHP.  Mary has given multiple national presentations about oncology pharmacy topics at various national meetings, and serves as a practitioner surveyor for ASHP PGY2 Oncology Pharmacy residency accreditation surveys. Mary was honored to receive the UW Health Pharmacy Department Preceptor of the Year Award in 2015 and the UW Department of Medicine Division of Hematology, Medical Oncology and Palliative Care Award for Extraordinary Service to the Division for 2016-17.

Target Audience
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity number 0465-0000-19-033-H04-P.

BC3: Maintenance Therapy After Hematopoietic Cell Transplantation in AML: The Old, the New, and the Future

Description: Despite the recent increase in newly approved agents to treat acute myeloid leukemia (AML), the need for hematopoietic stem cell transplant (HSCT) remains an essential consolidation treatment for high-risk patients. Unfortunately, despite this potentially curable treatment, relapses following HSCT remain a major cause of treatment failure. This session will give an overview of the relapse risk post-HSCT in AML and a detailed review of the currently available literature on the use of maintenance therapy. The presenter will discuss the role of hypomethylating agents azacitidine and decitabine; FLT3 inhibitors sorafenib, midostaurin, and quizartinib; and future agents, including panobinostat and an oral formulation of azacitidine. The challenges in using maintenance therapy in clinical practice will also be addressed.

Learning Objectives

  • Demonstrate the need for maintenance therapy after allogeneic stem cell transplantation in acute myeloid leukemia
  • Apply the data supporting the use of post-transplant maintenance therapy with hypomethylating agents, FLT3 inhibitors, lenalidomide, and panobinostat
  • Choose post-transplant maintenance therapy based on patient and disease characteristics
  • Predict toxicities of post-transplant maintenance therapy

Speaker: Amanda Seddon, PharmD BCOP BCPS

 amanda seddon

Amanda N Seddon, PharmD, BCPS, BCOP is an assistant professor in the Department of Pharmacy Practice and Midwestern University, Chicago College of Pharmacy and clinical pharmacy specialist in hematology, oncology, and cellular therapy at Rush University Medical Center in Chicago, IL. She earned her Doctorate of Pharmacy degree from the University of Illinois at Chicago College of Pharmacy where she also completed a PGY1 pharmacy residency and a PGY2 adult oncology residency at Memorial Sloan Kettering Cancer Center. Amanda serves as Chair-Elect on ASBMT Pharmacy SIG’s Membership and Awards Working Committee and is a committee member of HOPA’s Standard Committee. She has been an active member of HOPA for several years.

Target Audience
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-034-H04-P.

 

BC4: Current Strategies in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

Description: This session will review recent literature and FDA approvals that have shaped the pharmacologic management of CINV. Topics covered will include current consensus guidelines; the use of recently approved agents such as rolapitant, netupitant, fosnetupitant, aprepitant emulsion, and granisetron extended-release injection and their emerging place in therapy; and a discussion of multiple clinical controversies that could have an impact on patient care. Practical approaches to prophylaxis and control of breakthrough CINV using brief patient cases and audience responses will enhance active learning and highlight the role of the oncology pharmacist in the management of CINV.

Learning Objectives

  • Assess current CINV consensus guidelines
  • Analyze the emerging place of recently approved agents in CINV therapy
  • Interpret relevant clinical controversies regarding the management of CINV
  • Demonstrate the role of the pharmacist in the management of CINV using a patient case approach

Speaker: Michael Berger, PharmD BCOP

 michael berger

Michael J. Berger, PharmD BCOP, is a clinical specialty pharmacist for the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center. He holds an appointment of Clinical Assistant Professor at the OSU College of Pharmacy where he teaches oncology therapeutics and precepts PharmD students.

For the last 16 years, Dr. Berger has worked at a comprehensive, ambulatory oncology clinic specializing in the management of patients with breast cancer. He has pioneered clinical pharmacy services within the breast medical oncology clinic with a focus on the appropriate and safe use of oral chemotherapy and hormonal medications, and has been instrumental in the development of guidelines and services aimed at improving education and supportive care management of patients. In addition to research and resident precepting, he serves on various committees at his institution, is a member of the Hematology Oncology Pharmacy Association (HOPA), and serves as vice-chair on the National Comprehensive Cancer Network (NCCN) Antiemesis panel.

Michael J. Berger, PharmD BCOP, is a clinical specialty pharmacist for the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center. He holds an appointment of Clinical Assistant Professor at the OSU College of Pharmacy where he teaches oncology therapeutics and precepts PharmD students.

Target Audience
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.0 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-19-035-H04-P.

 

BC5: Advances in Breast Cancer: Are We Moving the Needle to Better Survival?

Description: Breast cancer mortality is falling as a result of earlier detection, advancements in surgical techniques, improved delivery of radiotherapy, and better adjuvant medical therapies. Despite these improvements, breast cancer remains the most common women’s cancer and is the second most common cause of death in women. This session will focus on the medical treatment of breast cancer in the adjuvant and metastatic setting, with particular attention to recent advances in the role of extended adjuvant therapy and new drug therapies such as olaparib and CD4/6 inhibitors.

Learning Objectives

  • Analyze the role of chemotherapy after resection of local regional breast cancer and recurrence risk
  • Illustrate the appropriate patient population for extended adjuvant therapy in breast cancer breast cancer subtypes
  • Outline the role of CDK 4/6 inhibitors and PARP inhibitors in metastatic breast cancer
  • Discuss role of immune checkpoint inhibitor in advanced triple negative breast cancer

Speaker: Sandra Cuellar, PharmD BCOP

 sandra cuellar

Sandra Cuellar, PharmD, BCOP, is a Clinical Assistant Professor in the Department of Pharmacy Practice at the University of Illinois at Chicago (UIC) College of Pharmacy.  Dr. Cuellar has been active in the field of hematology/oncology for 16 years.  She is the coordinator and clinical assistant professor for oncology therapeutics.  Dr. Cuellar received her Bachelor of Liberal Arts from Augustana College in Rock Island, Illinois, followed by her PharmD. degree from the University of Illinois at Chicago College of Pharmacy.  She then completed a Pharmacy Practice Residency at University of Kentucky Chandler Medical Center.  Following her residency, she completed a specialty oncology residency at MD Anderson Cancer Center in Houston, Texas.  She currently is the clinical pharmacist in the Out-Patient Cancer Center and is also the director of the oncology specialty residency program at UIC.  Dr. Cuellar is an editor at large for Journal of Hematology Oncology Pharmacy and is involved in research, consulting and publications in the field of hematology/oncology.

Target Audience
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity number 0465-0000-19-036-H04-P.

 

BC6: Leukemia Is Coming: The Battle of Targeted Therapies in Acute Myeloid Leukemia

Description: For more than 40 years, the war against acute myeloid leukemia (AML) raged, with little progress made in the standard treatment artillery, 7+3. This status changed in the past 2 years, with five novel agents added to the arsenal. This session will take an in-depth look at these targeted therapies, their mechanisms and pathways, unique toxicity profiles, and pharmcoeconomic impact. Key agents awaiting FDA decisions in early 2019 will also be discussed. We will debate clinical controversies in treatment selection and glean new understanding of the pharmacists' role in the management of AML in this new era. Let the battle of targeted therapies begin.

 Learning Objectives

  • Demonstrate an understanding of the pharmacology of newly approved targeted therapies in Acute Myeloid Leukemia (AML)
  • Produce a management care plan, from regimen selection to modification based on patient-specific factors or toxicity
  • Illustrate the financial toxicity associated with recent advances in the treatment of AML patients
  • Interpret current investigative options for the management of AML

Speakers: Bernard Marini, PharmD BCOP
Kayleigh Marx, PharmD RPh BCOP

 bernard marini

Bernard Marini, PharmD, BCOP is a Clinical Pharmacist specialist in Hematology and Adjunct Clinical Assistant Professor at the University of Michigan. He completed Pharmacy School, a PGY1 Pharmacy Practice Residency, and a PGY2 Hematology/Oncology Pharmacy at the University of Michigan, thereafter taking a position as the inpatient hematology clinical pharmacist at U of M in 2014. Dr. Marini is an expert in the treatment of acute leukemias and serves as a vital member of the leukemia tumor board and leukemia research group at Michigan Medicine. Dr. Marini is heavily involved in research aiming to improve outcomes in acute leukemia patients and has over 30 peer-reviewed publications.

kayleigh marx

Kayleigh Marx, PharmD, BCOP is a Clinical Pharmacy specialist in Leukemia at the University of Texas MD Anderson Cancer Center. She completed pharmacy school at the University of Georgia, and a PGY1 Pharmacy Practice Residency and PGY2 Hematology/Oncology Pharmacy Residency at the University of Kentucky. Dr. Marx is an outspoken advocate for evidence-based care, actively participating in multidisciplinary research within the leukemia group and infectious disease group at MD Anderson. As chair of the PGY2 Hematology/Oncology Resident Research committee as well as chair of the Research Abstract Review Subcommittee at HOPA, Dr. Marx strives to foster an environment enriched in high level pharmacist-performed research for the betterment of all patients with cancer.

Target Audience
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity number 0465-0000-19-037-H04-P.

 

BC7: Updates in the Management of Colorectal Cancer

Description: This session will review new recommendations in the treatment of colorectal cancer and equip clinical practitioners with knowledge they can apply to their practices. Topics include risk factors and risk reduction strategies; updates in screening recommendations for normal risk populations; and the application of molecular biomarkers such as MSI, KRAS and BRAF in treatment of both early- and late-stage disease. The IDEA collaboration and how results allow for the first individualization of colorectal cancer treatment based on patient disease characteristics, co-morbidities, and preference will also be examined.

Learning Objectives

  • Demonstrate an understanding of risk factors and risk reduction strategies for colorectal cancer, including updated screening recommendations by risk category
  • Employ current recommendations on genetic and molecular testing in metastatic colorectal treatment planning
  • Apply results of microsatellite instability, KRAS, BRAF, and NRAS testing in colorectal cancer treatment planning
  • Interpret results of the IDEA collaboration and respective impact on adjuvant colorectal cancer treatment

 Speaker: Amber Draper, PharmD BCOP

Amber Draper completed her pharmacy school training at Mercer University College of Pharmacy. She then went on to complete both a PGY-1 general and PGY-2 oncology/hematology residency at UAB Hospital. She is currently the Clinical Pharmacy Specialist in the GI malignancy clinic of Emory Winship Cancer Institute in Atlanta where her role involves collaboration with the healthcare team to ensure medications prescribed for patients are appropriate and effective, bringing about positive health outcomes. She maintains an active role in pharmacy driven research at Winship with a focus in GI malignancies and supportive care.

Target Audience
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1.25 contact hour (.125 CEUs) under the ACPE universal activity 0465-0000-19-038-H04-P.

 

 

 

xs
sm
md
lg